Reported Earnings • May 28
Full year 2026 earnings released: EPS: ₹0.32 (vs ₹8.22 loss in FY 2025) Full year 2026 results: EPS: ₹0.32 (up from ₹8.22 loss in FY 2025). Revenue: ₹583.9m (up 7.8% from FY 2025). Net income: ₹3.93m (up ₹93.1m from FY 2025). Profit margin: 0.7% (up from net loss in FY 2025). Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Announcement • May 21
Banka BioLoo Limited to Report Q4, 2026 Results on May 26, 2026 Banka BioLoo Limited announced that they will report Q4, 2026 results on May 26, 2026 New Risk • May 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (14% operating cash flow to total debt). Earnings have declined by 66% per year over the past 5 years. Market cap is less than US$10m (₹897.1m market cap, or US$9.43m). Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change). Reported Earnings • Feb 16
Third quarter 2026 earnings released: ₹0.14 loss per share (vs ₹1.34 loss in 3Q 2025) Third quarter 2026 results: ₹0.14 loss per share (improved from ₹1.34 loss in 3Q 2025). Revenue: ₹153.2m (up 9.1% from 3Q 2025). Net loss: ₹1.49m (loss narrowed 90% from 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 86 percentage points per year, which is a significant difference in performance. Announcement • Feb 05
Banka BioLoo Limited to Report Q3, 2026 Results on Feb 12, 2026 Banka BioLoo Limited announced that they will report Q3, 2026 results on Feb 12, 2026 New Risk • Nov 18
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₹852.0m (US$9.62m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (14% operating cash flow to total debt). Earnings have declined by 68% per year over the past 5 years. Market cap is less than US$10m (₹852.0m market cap, or US$9.62m). Reported Earnings • Nov 17
Second quarter 2026 earnings released Second quarter 2026 results: Revenue: ₹130.6m (up 5.3% from 2Q 2025). Net loss: ₹10.8m (loss narrowed 82% from 2Q 2025). Board Change • Nov 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Non-Executive Woman Independent Director Geeta Goti was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 14
First quarter 2026 earnings released First quarter 2026 results: Revenue: ₹121.9m (down 5.4% from 1Q 2025). Net income: ₹21.0k (down 99% from 1Q 2025). Profit margin: 0% (down from 2.3% in 1Q 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 138 percentage points per year, which is a significant difference in performance. Announcement • Aug 11
Banka BioLoo Limited, Annual General Meeting, Sep 10, 2025 Banka BioLoo Limited, Annual General Meeting, Sep 10, 2025, at 15:00 Indian Standard Time. New Risk • Jul 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (2.5% operating cash flow to total debt). Earnings have declined by 64% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Market cap is less than US$100m (₹907.4m market cap, or US$10.5m). New Risk • Mar 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (8.5% operating cash flow to total debt). Earnings have declined by 60% per year over the past 5 years. Market cap is less than US$10m (₹690.3m market cap, or US$7.92m). Minor Risk Share price has been volatile over the past 3 months (8.0% average weekly change). Reported Earnings • Feb 15
Third quarter 2025 earnings released: ₹1.34 loss per share (vs ₹0.65 profit in 3Q 2024) Third quarter 2025 results: ₹1.34 loss per share (down from ₹0.65 profit in 3Q 2024). Revenue: ₹141.5m (up 1.4% from 3Q 2024). Net loss: ₹14.6m (down 308% from profit in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 110 percentage points per year, which is a significant difference in performance. New Risk • Feb 14
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₹848.5m (US$9.78m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (8.8% operating cash flow to total debt). Earnings have declined by 53% per year over the past 5 years. Market cap is less than US$10m (₹848.5m market cap, or US$9.78m). Reported Earnings • Nov 15
Second quarter 2025 earnings released: ₹5.65 loss per share (vs ₹1.12 profit in 2Q 2024) Second quarter 2025 results: ₹5.65 loss per share (down from ₹1.12 profit in 2Q 2024). Revenue: ₹124.9m (up 9.1% from 2Q 2024). Net loss: ₹61.3m (down ₹73.5m from profit in 2Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 99 percentage points per year, which is a significant difference in performance. Reported Earnings • Aug 15
First quarter 2025 earnings released: ₹2.15 loss per share (vs ₹2.15 loss in 1Q 2024) First quarter 2025 results: ₹2.15 loss per share (in line with 1Q 2024). Revenue: ₹84.5m (up 2.1% from 1Q 2024). Net loss: ₹23.3m (flat on 1Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 101 percentage points per year, which is a significant difference in performance. Announcement • Jul 06
Banka BioLoo Limited, Annual General Meeting, Aug 08, 2024 Banka BioLoo Limited, Annual General Meeting, Aug 08, 2024, at 15:00 Indian Standard Time. Reported Earnings • Jun 04
Full year 2024 earnings released: ₹0.60 loss per share (vs ₹2.35 profit in FY 2023) Full year 2024 results: ₹0.60 loss per share (down from ₹2.35 profit in FY 2023). Revenue: ₹504.9m (up 19% from FY 2023). Net loss: ₹6.71m (down 126% from profit in FY 2023). Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings. Reported Earnings • Feb 10
Third quarter 2024 earnings released: EPS: ₹0.65 (vs ₹1.00 in 3Q 2023) Third quarter 2024 results: EPS: ₹0.65 (down from ₹1.00 in 3Q 2023). Revenue: ₹140.7m (up 31% from 3Q 2023). Net income: ₹7.01m (down 35% from 3Q 2023). Profit margin: 5.0% (down from 10% in 3Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has increased by 23% per year, which means it is well ahead of earnings. Reported Earnings • Nov 16
Second quarter 2024 earnings released: EPS: ₹1.12 (vs ₹0.81 in 2Q 2023) Second quarter 2024 results: EPS: ₹1.12 (up from ₹0.81 in 2Q 2023). Revenue: ₹115.4m (down 6.6% from 2Q 2023). Net income: ₹12.2m (up 39% from 2Q 2023). Profit margin: 11% (up from 7.1% in 2Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has increased by 23% per year, which means it is well ahead of earnings. Board Change • Oct 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 3 highly experienced directors. Independent Non-Executive Director Anil Sharma was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Sep 02
Banka BioLoo Limited, Annual General Meeting, Sep 25, 2023 Banka BioLoo Limited, Annual General Meeting, Sep 25, 2023, at 15:00 Indian Standard Time. Agenda: To receive, consider and adopt the audited financial statements (both standalone and consolidated) of the Company for the financial year ended 31 March 2023, together with the reports of the Board of Directors and the Auditors thereon; to approve the Banka BioLoo Limited Employees Stock Option Plan - 2023; to appoint a Director in place of Ms. Namita Banka who retires by rotation, and being eligible, offers herself for re-appointment; to approve grant of Options under the Banka BioLoo Limited Employees Stock Option Plan - 2023 to the eligible employees of the Subsidiary Companies of the Company; and to consider other matters. New Risk • Aug 13
New minor risk - Revenue size The company makes less than US$5m in revenue. Total revenue: ₹395m (US$4.8m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 28% per year over the past 5 years. Market cap is less than US$10m (₹755.5m market cap, or US$9.11m). Minor Risk Revenue is less than US$5m (₹395m revenue, or US$4.8m). Reported Earnings • Aug 12
First quarter 2024 earnings released: ₹2.15 loss per share (vs ₹0.52 profit in 1Q 2023) First quarter 2024 results: ₹2.15 loss per share (down from ₹0.52 profit in 1Q 2023). Revenue: ₹84.5m (down 24% from 1Q 2023). Net loss: ₹23.3m (down ₹28.9m from profit in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings. Reported Earnings • Jun 01
Full year 2023 earnings released: EPS: ₹2.39 (vs ₹3.02 in FY 2022) Full year 2023 results: EPS: ₹2.39 (down from ₹3.02 in FY 2022). Revenue: ₹430.5m (up 11% from FY 2022). Net income: ₹25.4m (down 18% from FY 2022). Profit margin: 5.9% (down from 8.0% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has increased by 46% per year, which means it is well ahead of earnings. Reported Earnings • Feb 14
Third quarter 2023 earnings released: EPS: ₹1.00 (vs ₹0.51 in 3Q 2022) Third quarter 2023 results: EPS: ₹1.00 (up from ₹0.51 in 3Q 2022). Revenue: ₹108.1m (up 7.5% from 3Q 2022). Net income: ₹10.9m (up 107% from 3Q 2022). Profit margin: 10.0% (up from 5.2% in 3Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has increased by 44% per year, which means it is well ahead of earnings. Reported Earnings • Nov 20
Second quarter 2023 earnings released: EPS: ₹0.81 (vs ₹0.87 in 2Q 2022) Second quarter 2023 results: EPS: ₹0.81 (down from ₹0.87 in 2Q 2022). Revenue: ₹125.0m (up 21% from 2Q 2022). Net income: ₹8.79m (flat on 2Q 2022). Profit margin: 7.0% (down from 8.6% in 2Q 2022). The decrease in margin was driven by higher expenses. Valuation Update With 7 Day Price Move • Sep 07
Investor sentiment improved over the past week After last week's 18% share price gain to ₹83.15, the stock trades at a trailing P/E ratio of 29.9x. Average trailing P/E is 26x in the Commercial Services industry in India. Total returns to shareholders of 138% over the past three years. Reported Earnings • Aug 12
First quarter 2023 earnings released: EPS: ₹0.52 (vs ₹0.63 in 1Q 2022) First quarter 2023 results: EPS: ₹0.52 (down from ₹0.63 in 1Q 2022). Revenue: ₹112.1m (up 40% from 1Q 2022). Net income: ₹5.59m (down 13% from 1Q 2022). Profit margin: 5.0% (down from 8.0% in 1Q 2022). The decrease in margin was driven by higher expenses. Valuation Update With 7 Day Price Move • Jul 14
Investor sentiment improved over the past week After last week's 18% share price gain to ₹79.60, the stock trades at a trailing P/E ratio of 27.8x. Average trailing P/E is 19x in the Commercial Services industry in India. Total returns to shareholders of 111% over the past three years. Valuation Update With 7 Day Price Move • Jun 20
Investor sentiment deteriorated over the past week After last week's 15% share price decline to ₹61.65, the stock trades at a trailing P/E ratio of 21.5x. Average trailing P/E is 19x in the Commercial Services industry in India. Total returns to shareholders of 54% over the past three years. Reported Earnings • Jun 03
Full year 2022 earnings released: EPS: ₹3.02 (vs ₹2.14 in FY 2021) Full year 2022 results: EPS: ₹3.02 (up from ₹2.14 in FY 2021). Revenue: ₹392.0m (up 29% from FY 2021). Net income: ₹31.1m (up 41% from FY 2021). Profit margin: 7.9% (up from 7.2% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has increased by 19% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Mar 28
Investor sentiment improved over the past week After last week's 17% share price gain to ₹77.90, the stock trades at a trailing P/E ratio of 29x. Average trailing P/E is 24x in the Commercial Services industry in India. Total returns to shareholders of 149% over the past three years. Reported Earnings • Feb 17
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: ₹0.51 (down from ₹0.51 in 3Q 2021). Revenue: ₹102.0m (up 19% from 3Q 2021). Net income: ₹5.26m (flat on 3Q 2021). Profit margin: 5.2% (down from 6.1% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has increased by 35% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Jan 03
Investor sentiment improved over the past week After last week's 16% share price gain to ₹82.35, the stock trades at a trailing P/E ratio of 32.6x. Average trailing P/E is 22x in the Commercial Services industry in India. Total returns to shareholders of 157% over the past three years. Valuation Update With 7 Day Price Move • Sep 01
Investor sentiment improved over the past week After last week's 22% share price gain to ₹77.45, the stock trades at a trailing P/E ratio of 39.1x. Average trailing P/E is 19x in the Commercial Services industry in India. Total returns to shareholders of 125% over the past three years. Valuation Update With 7 Day Price Move • Jul 22
Investor sentiment improved over the past week After last week's 21% share price gain to ₹77.70, the stock trades at a trailing P/E ratio of 36.1x. Average trailing P/E is 21x in the Commercial Services industry in India. Total returns to shareholders of 139% over the past three years. Reported Earnings • May 23
Full year 2021 earnings released: EPS ₹2.15 (vs ₹5.88 in FY 2020) The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹310.3m (down 35% from FY 2020). Net income: ₹22.0m (down 64% from FY 2020). Profit margin: 7.1% (down from 13% in FY 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • May 11
Investor sentiment improved over the past week After last week's 25% share price gain to ₹77.00, the stock trades at a trailing P/E ratio of 15.8x. Average trailing P/E is 15x in the Commercial Services industry in India. Total returns to shareholders of 71% over the past three years. Valuation Update With 7 Day Price Move • Feb 02
Investor sentiment improved over the past week After last week's 18% share price gain to ₹72.50, the stock is trading at a trailing P/E ratio of 14.9x, up from the previous P/E ratio of 12.7x. This compares to an average P/E of 13x in the Commercial Services industry in India. Total returns to shareholders over the past year are 155%. Is New 90 Day High Low • Feb 01
New 90-day high: ₹69.05 The company is up 72% from its price of ₹40.15 on 03 November 2020. The Indian market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Commercial Services industry, which is up 12% over the same period. Is New 90 Day High Low • Jan 05
New 90-day high: ₹59.60 The company is up 90% from its price of ₹31.45 on 07 October 2020. The Indian market is up 20% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Commercial Services industry, which is up 10.0% over the same period. Valuation Update With 7 Day Price Move • Jan 04
Investor sentiment improved over the past week After last week's 19% share price gain to ₹56.80, the stock is trading at a trailing P/E ratio of 11.7x, up from the previous P/E ratio of 9.8x. This compares to an average P/E of 13x in the Commercial Services industry in India. Valuation Update With 7 Day Price Move • Dec 16
Investor sentiment improved over the past week After last week's 22% share price gain to ₹54.05, the stock is trading at a trailing P/E ratio of 11.1x, up from the previous P/E ratio of 9.1x. This compares to an average P/E of 12x in the Commercial Services industry in India. Total returns to shareholders over the past year are 120%. Is New 90 Day High Low • Dec 08
New 90-day high: ₹44.20 The company is up 1.0% from its price of ₹43.85 on 09 September 2020. The Indian market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Commercial Services industry, which is up 22% over the same period. Valuation Update With 7 Day Price Move • Nov 02
Market bids up stock over the past week After last week's 21% share price gain to ₹38.25, the stock is trading at a trailing P/E ratio of 6.5x, up from the previous P/E ratio of 5.4x. This compares to an average P/E of 13x in the Commercial Services industry in India. Total returns to shareholders over the past year are 15%. Is New 90 Day High Low • Oct 15
New 90-day low: ₹27.90 The company is down 2.0% from its price of ₹28.50 on 13 July 2020. The Indian market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Commercial Services industry, which is down 1.0% over the same period. Announcement • Sep 20
Banka Bioloo Limited Approves Appointment of Directors Banka BioLoo Limited at AGM held on September 16, 2020 approved appointment of Ms. Aparajita Agrawal, (DIN 08789734) as a Non-Executive Independent Director of the company. And the company also approved Appointment of Dr. Basava Raju Dumpala (DIN 03303947) as a Non-Executive Independent Director of the Company for a consecutive term of five year with effect form September 17, 2020.